Background: Ataxia Teleangiectasia [AT] is a rare neurodegenerative disease characterized by early onset ataxia, oculocutaneous teleangiectasias, immunodeficiency, recurrent infections, radiosensitivity and proneness to cancer. No therapies are available for this devastating disease. Recent observational studies in few patients showed beneficial effects of short term treatment with betamethasone. To avoid the characteristic side effects of long-term administration of steroids we developed a method for encapsulation of dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) allowing slow release of dexamethasone for up to one month after dosing. Aims of the study were: the assessment of the effect of EryDex in improving neurological symptoms and adaptive behaviour of AT patients; the safety and tolerability of the therapy.Methods: Twenty two patients (F:M = 1; mean age 11.2 ± 3.5) with a confirmed diagnosis of AT and a preserved or partially supported gait were enrolled for the study. The subjects underwent for six months a monthly infusion of EryDex. Ataxia was assessed by the International Cooperative Ataxia Rating Scale (ICARS) and the adaptive behavior by Vineland Adaptive Behavior Scales (VABS). Clinical evaluations were performed at baseline and 1, 3, and 6 months.Results: An improvement in ICARS (reduction of the score) was detected in the intention-to-treat (ITT) population (n = 22; p = 0.02) as well as in patients completing the study (per protocol PP) (n = 18; p = 0.01), with a mean reduction of 4 points (ITT) or 5.2 points (PP). When compared to baseline, a significant improvement were also found in VABS (increase of the score) (p < 0.0001, ITT, RMANOVA), with statistically significant increases at 3 and 6 months (p < 0.0001). A large inter-patient variability in the incorporation of DSP into erythrocytes was observed, with an evident positive effect of higher infusion dose on ICARS score decline. Moreover a more marked improvement was found in less neurologically impaired patients. Finally, a 19 month-extension study involving a subgroup of patients suggested that Erydex treatment can possibly delay the natural progression of the disease.EryDex was well tolerated; the most frequent side effects were common AT pathologies.Conclusions: EryDex treatment led to a significant improvement in neurological symptoms, without association with the typical steroid side effects.Trial registration: Current Controlled Trial2010-022315-19SpA
There remains great interest in understanding the relationship between visual impairment (VI) and autism spectrum disorder (ASD) due to the extraordinarily high prevalence of ASD in blind and visually impaired children. The broad variability across individuals and assessment methodologies have made it difficult to understand whether autistic-like symptoms shown by some children with VI might reflect the influence of the visual deficit, or represent a primary neurodevelopmental condition that occurs independently of the VI itself. In the absence of a valid methodology adapted for the visually impaired population, diagnosis of ASD in children with VI is often based on non-objective clinical impression, with inconclusive prevalence data. In this review, we discuss the current state of knowledge and suggest directions for future research.
Action Observation Treatment is a novel rehabilitation approach exploiting a neurophysiological mechanism that allows one to recruit the neural structures sub-serving action execution during the me...
9 March 2017 in Child: Care, Health and Development
Incontinentia pigmenti (IP, MIM 308300) is a rare X-linked genodermatosis that not only included well-defined dermatological features but also central nervous system abnormalities. Although IP is usually lethal in males, occurrences of the disease in boys have been reported, but phenotype has not been well characterized. We report on neurological, electroencephalographic (EEG) and neuroimaging findings in a male infant with IP and a 47, XXY karyotype. The baby presented at birth with generalized vesiculopustular eruption and the diagnosis of IP was confirmed by skin biopsy and by IKBKG gene mutation. Chromosome analysis was consistent with the diagnosis of Klinefelter syndrome. At 2 months of age, he experienced a convulsive status epilepticus managed with endovenous phenytoin and phenobarbital (PB). Magnetic resonance imaging revealed multiple acute phase spotty high-intensity lesions on diffusion-weighted images (DWI) involving both cerebral hemispheres, compatible with multiple cerebral infarctions. Oral PB gave seizure control for 2 months, when he developed daily clusters of seizures characterized by eye twitching and extensor spasms of one arm lasted few seconds. EEG showed background disorganization and multifocal abnormalities with focal clinical and electrographic seizures. Carbamazepine was started but seemed ineffective, and the frequency of seizures was reduced after vigabatrin was added. In follow-up evaluation, clinical picture was characterized by severe developmental delay with poor spontaneous motility, generalized hypertonia, severe visual deficit due to bilateral retinal detachment, and poor feeding with difficulty swallowing. Due to the clinical variability of this rare condition, awareness of the association between IP and epilepsy will help to plan treatment for both conditions.